Arbutus Biopharma Corp 8K

Arbutus Biopharma plans a modified Dutch Auction tender offer to repurchase up to US$230 million of its common shares at US$5.00–US$5.75 per share, expected to run from late August to late September 2026, subject to regulatory exemptive relief.

Arbutus Biopharma Corporation announced its intention to commence a modified Dutch Auction tender offer to repurchase up to US$230 million of its common shares, at prices between US$5.00 and US$5.75 per share in cash, funded from cash on hand and expected to launch on or about August 24, 2026 and expire on or about September 29, 2026, subject to receipt of required exemptive relief in the U.S. and Canada and other conditions; J.P. Morgan Securities LLC will act as dealer-manager, with Georgeson LLC as information agent and TSX Trust Company as depositary.

Filing Facts

CIK

1447028

Ticker

ABUS

Form

8K

Source Type

fda

Accession

0001104659-26-099390

Alert Tier

6